BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 7907872)

  • 1. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys.
    Matsuda M; Sakashita M; Mizuki Y; Yamaguchi T; Fujii T; Sekine Y
    Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
    Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
    Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
    Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the first-pass metabolism of ebastine in rats.
    Fujii T; Matsumoto S; Hatoyama T; Miyazaki H
    Arzneimittelforschung; 1997 Aug; 47(8):949-53. PubMed ID: 9296281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, distribution, metabolism and excretion of [14C]ebastine after repeated oral administration in rats.
    Fujii T; Tanaka K; Matsumoto S; Hatoyama T; Nomura N; Tagawa M; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):538-43. PubMed ID: 7912072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
    Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
    Noveck RJ; Preston RA; Swan SK
    Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine.
    Tamai I; Kido Y; Yamashita J; Sai Y; Tsuji A
    J Drug Target; 2000; 8(6):383-93. PubMed ID: 11328664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine.
    Van Rooij J; Schoemaker HC; Bruno R; Reinhoudt JF; Breimer DD; Cohen AF
    Br J Clin Pharmacol; 1993 Jun; 35(6):661-3. PubMed ID: 8101096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of ebastine in children.
    Simons FE; Watson WT; Simons KJ
    J Pediatr; 1993 Apr; 122(4):641-6. PubMed ID: 8096545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects.
    Huang MY; Argenti D; Wilson J; Garcia J; Heald D
    Am J Ther; 1998 May; 5(3):153-8. PubMed ID: 10099053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants.
    Shon JH; Yeo CW; Liu KH; Lee SS; Cha IJ; Shin JG
    J Clin Pharmacol; 2010 Feb; 50(2):195-204. PubMed ID: 19841159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
    Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
    Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.
    Vincent J; Liminana R; Meredith PA; Reid JL
    Br J Clin Pharmacol; 1988 Nov; 26(5):497-502. PubMed ID: 2905150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administrations in dogs and monkeys.
    Sakashita M; Mizuki Y; Yamaguchi T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Aug; 43(8):864-6. PubMed ID: 8216444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological study of ebastine, a novel histamine H1-receptor antagonist].
    Yakuo I; Ishii K; Seto Y; Imano K; Takeyama K; Nakamura H; Karasawa T
    Nihon Yakurigaku Zasshi; 1994 Mar; 103(3):121-35. PubMed ID: 7511558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs.
    Puigdemont A; Queralt M; Jansat JM; Martinez-Tobed A
    J Pharm Pharmacol; 1994 Jul; 46(7):596-9. PubMed ID: 7996390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.
    Chaikin P; Gillen MS; Malik M; Pentikis H; Rhodes GR; Roberts DJ
    Br J Clin Pharmacol; 2005 Mar; 59(3):346-54. PubMed ID: 15752381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.